Safety of a Contraceptive Copper Vaginal Ring
- Sponsor
- Elle, MD Biotechnologies Inc.
- Study ID
- NCT07666997
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Birth Control
- Contraception
- Pregnancy Prevention
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 50 Years
- Healthy Volunteers
- Accepted
Interventions
- Vaginal Ring — DEVICEThe copper vaginal ring (CVR) is a non-hormonal vaginal ring designed for prevention of pregnancy
Study Details
Many birth control options today come with unwanted side effects or risks. Hormonal methods can affect both mental and physical health, while devices like copper IUDs carry risks such as uterine perforation or infection. This study is testing a new option: a copper vaginal ring (CVR) - a non-hormonal, non-invasive contraceptive that can be self-inserted, similar to a other vaginal rings like NuvaRing or Annovera. The main goal of this study is to assess whether the copper vaginal ring is safe to use. Researchers will also look at how comfortable and easy it is to use, whether participants follow the instructions, and how much copper accumulates in cervical mucus and vaginal fluid during use. The study will enroll 8 women of childbearing age. Participants wear the ring continuously for 28 days, inserting it on Day 5 of their menstrual cycle. Over the course of the study, participants will attend 8 in-person clinic visits, which include pelvic exams, vaginal swabs, blood draws, and cervical mucus collection. On the day the ring is removed (Day 28), small tissue samples (biopsies) are taken from the vagina and uterine lining. At the end of the study, participants will complete a short survey about their experience with the ring.
Key Dates
- First listed
- Jun 24, 2026
- Start date
- Oct 1, 2026
- Status verified
- Jun 2026
- Primary completion
- Feb 28, 2027
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 8 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: CVRParticipants in the CVR arm will use the Copper Vaginal Ring for 28 days
Primary Outcome Measure
Adverse Events [Safety] [ Time Frame: From enrollment to the end of treatment on Day 35 ]
Central Contacts
- Teresa Flaxman, PhD(613)738-8400
Related Studies
- Evaluation of the Efficacy, Safety, and Tolerability of LevoCeptPHASE3 · Not Yet Recruiting · Sebela Women's Health Inc. · Berkeley, California
- Implementation of a Patient-centered, Reproductive Planning Decision Support Tool (MyPath) Among Women With Substance Use Disorder in the Immediate Postpartum PeriodRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Etonogestrel Implant as Emergency ContraceptionPHASE4 · Recruiting · University of Colorado, Denver · Aurora, Colorado
- Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day StartPHASE4 · Recruiting · University of Utah · San Jose, California